BIOMARIN PHARMACEUTICAL INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 81.64 USD | -0.65% |
|
-7.88% | -15.32% |
Presenter SpeechGeoffrey Meacham (Analysts)Good morning. Welcome to the third day of the Bank ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
Pharmaceuticals
Calendar
2024-05-21
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
82.17
USD
Average target price
110
USD
Spread / Average Target
+33.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.32% | 15.59B | |
| -4.66% | 87.53B | |
| +1.32% | 40.42B | |
| -19.06% | 29.48B | |
| +57.86% | 25.43B | |
| -17.89% | 11.49B | |
| -43.00% | 11.3B | |
| -9.14% | 11.1B | |
| +5.24% | 8.75B | |
| -8.42% | 7.99B |
- Stock Market
- Equities
- BMRN Stock
- News BioMarin Pharmaceutical Inc.
- Transcript : BioMarin Pharmaceutical Inc. Presents at Bank of America 2022 Healthcare Conference, May-12-2022 08
